Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
25 results
D1.380 - Quicker EASI 75 or greater decline of DLQI - is it significant? Comparison of dupilumab treatment among children and adults in two centres in Cracow
D1.383 - Nonimmediate hypersensitivity reaction to Lanadelumab in a patient with Hereditary Angioedema: a case report
D1.384 - Long-term Prophylaxis with Lanadelumab in Hereditary and Acquired Angioedema: A Single-Center Retrospective-Prospective “Real-Life” Analysis
D1.385 - Dupilumab Treatment Effects on Atopic Manifestations in Patients with Inborn Errors of Immunity
D1.386 - Impact of dupilumab on allergen specific immunoglobulin E production
Pagination
First page
First
Previous page
Previous
Page
1
Current page
2
Download the app
The congress at your fingertips
Available on
Download